Saturday, March 30, 2013

Neurocrine begins the Phase IIb Clinical trial for fibroids uterine treatment-San Diego Business Journal

Thursday, March 28, 2013

Neurocrine Biosciences Inc. initiated a Phase IIb Clinical trial to evaluate its drug based on the synthetic hormone that treats non-cancerous tumors of the uterus called uterine fibroids.

The drug, called Elagolix, is being developed jointly with pharmaceutical developer based in Chicago, that abbvie Neurocrine Biosciences Inc. has entered into a collaboration and license agreement for the drug in 2010. with Abbott Laboratories in 2010, before the yarn sector become a separate company, AbbVie.

Neurocrine Biosciences Abbott paid an advance of $75 million, with provisions to extend up to 480 million $, based on the additional development and events focused on the regulatory payments. Neurocrine Biosciences commercialization could bring an additional $ 50 million $, plus a percentage of sales in the world.

"Based on the positive results of the fibroids uterine Phase IIa trials, uterine AbbVie in Phase IIb Elagolix for fibroids has progressed," Kevin Gorman, president and CEO of Neurocrine Biosciences, said in a statement. "We are satisfied with this promotion, as well as the Phase III program in endometriosis, and I look forward further development of Elagolix in these two diseases States which have high needs unmet medical needs."

About 250,000 hysterectomies are performed each year, associated with uterine fibroids.

Neurocrine Biosciences, a company listed on the Nasdaq, has a market capitalization of 759 million $.

-Staff report the SDBJ


View the original article here

Sunday, March 24, 2013

Esyma drug for utrerine fibroids gets go-ahead - Scotsman

AppId is over the quota
AppId is over the quota

The drug, called Esmya, is the first oral treatment for uterine fibroids. These are benign tumours found in the uterus that can cause heavy menstrual bleeding, iron-deficiency anaemia, abdominal pain, an enlarged abdomen and bladder or bowel pressure, as well as infertility.

The drug gives women an option other than an injection for excessive bleeding and fibroid size reduction prior to surgery

The licence from the Scottish Medicines Consortium (SMC) means the drug can now be prescribed generally in treatment.

The advantages and cost benefits of Esmya were demonstrated in a comprehensive clinical trials programme prior to the SMC licensing it for prescription, with two of the most significant studies being published in the prestigious New England Journal of Medicine.

There is a genetic predisposition to the condition among black and Asian women, but it also affects a quarter of white females of reproductive age.

The SMC decision was welcomed by clinicians and patient groups.

Professor Mary Ann Lumsden, head of development medicine at the University of Glasgow and honorary consultant obstetrician and gynaecologist for NHS Greater Glasgow & Clyde, said: “It is a common condition.

“I do see a lot of women who do have fibroids and are significantly symptomatic, so it is important for women of Scotland.”

She stressed that there were still a lot of studies to be carried out on the drug and its uses, but added that it was a “major step forward”.


View the original article here

Monday, March 18, 2013

Halt Medical Announces The First Commercial Use Of the Acessa(TM) System - MarketWatch (press release)

AppId is over the quota
AppId is over the quota

LIVERMORE, Calif., March 12, 2013 /PRNewswire via COMTEX/ -- Halt Medical, Inc. announced that Dr. Jay M. Berman, M.D., FACOG, has performed the first commercial Acessa Procedure in the United States. The procedure is used for the treatment of uterine fibroids. Dr. Berman performed the procedure at the Berry Surgery Center in Farmington Hills, MI, an outpatient facility affiliated with the Detroit Medical Center's DMC Sinai-Grace Hospital.

"We are extremely happy that Dr. Berman, the Wayne State University Physician Group and Detroit Medical Center have begun introducing their patients to the Acessa Procedure," said Jeffrey M. Cohen, Halt Medical CEO. "The Acessa Procedure represents a major breakthrough in addressing one of the biggest unmet needs in women's health, uterine fibroids. Acessa is the only medical device that can be used by gynecologists to treat all fibroids."

Dr. Berman said, "Approximately 50 to 70 percent of women have uterine fibroids. Before the Acessa Technology, treatment involved cutting through layers of healthy tissue to gain access to the fibroids, or removing the uterus completely through a hysterectomy. However, research shows the majority of women choose to suffer through their symptoms rather than undergo surgery." Dr. Berman is Associate Professor, Director, Division of Gynecology, Department of Obstetrics and Gynecology, Wayne State University School of Medicine and Associate Chief Medical Officer, Clinical Operations, Wayne State University Physician Group.

The Acessa Procedure is a minimally invasive laparoscopic procedure that delivers radiofrequency energy to destroy the fibroids. After treatment, the fibroid is re-absorbed by the surrounding tissue. Acessa allows the surgeon to treat only the fibroids, while preserving normal function of the uterus. Patients typically go home the same day with little pain, and enjoy a rapid return to normal activities. More than 250 women have been successfully treated with Acessa.

"Any technology that gives us the ability to give women choices, in this case that spares the uterus and avoids the need for hysterectomy, has merit," said L. Andrea Coleman, M.D., chief of Obstetrics and Gynecology at DMC Sinai-Grace Hospital. "Sinai-Grace and the DMC have some of the best physicians in the country, and this is evidence of that. I applaud us for always being on the forefront of technology and for doing the work that is required to stay there."

About Halt Medical, Inc.

Founded in 2004, Halt Medical is a medical device company focused on establishing a new standard of care for women with symptomatic uterine fibroids. The Company has developed and launched the Acessa System and Procedure, using radiofrequency energy to destroy uterine fibroids. The results of both U.S. and international trials have led to the clearance of the product by the FDA for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The Acessa System also has regulatory approval to treat symptomatic uterine fibroids in the European Union, Canada, and Mexico. The Company is located in Brentwood, CA. For information about the Acessa System, please visit www.haltmedical.com. To connect with Halt Medical on Facebook visit www.facebook.com/acessasystem or on Twitter at www.twitter.com/acessasystem.

About Wayne State University Physician Group

The Wayne State University Physician Group (WSUPG) is one of southeast Michigan's largest non-profit multi-specialty physician practice groups, with more than 2,000 physicians providing primary and specialty medical services in close to 1 million patient visits annually. WSUPG has more than 100 locations, and affiliations with the Detroit Medical Center, Oakwood Healthcare System, Karmanos Cancer Center, Crittenton Hospital Medical Center, St. Joseph Mercy Oakland and St. John Providence Health System. As faculty members of the Wayne State University School of Medicine, WSUPG's physicians and staff are on the forefront of technology and bringing the latest in medical advancements to the bedside. In addition to its substantial clinical practice, WSUPG is training the Michigan physicians of tomorrow by providing instructors for more than 1,200 medical students and 900 residents each year. For more information or to make an appointment with a WSUPG doctor visit www.upgdocs.org. To connect with the Wayne State University Physician Group on Facebook visit www.facebook.com/wsupgdocs or on Twitter at www.twitter.com/wsupgdocs.

About DMC Sinai-Grace Hospital

DMC Sinai-Grace Hospital is a full-service hospital with 404 licensed beds and more than 700 physicians, 700 nurses, and 1,700 support staff. Services and capabilities include cardiology, emergency medicine, obstetrics and gynecology, urological services, psychiatry, radiation oncology, gerontology, physical medicine, and orthopedic surgery. Servicing more than 214,000 patients annually, Sinai-Grace also operates 25 ambulatory sites and surgery centers, including the Lahser and Berry Surgery Centers. Sinai-Grace serves as a teaching facility to more than 200 medical students each year, and is one of eight hospitals operated by the Detroit Medical Center (DMC). The DMC is proud to be the official health care services provider for the Detroit Tigers, Detroit Red Wings, and Detroit Pistons. For more information, visit www.sinaigrace.org. "Like" us on Facebook at www.facebook.com/sinaigrace or follow us on Twitter at @DMC_SinaiGrace.

SOURCE Halt Medical, Inc.

http://rt.prnewswire.com/rt.gif?NewsItemId=LA74924&Transmission_Id=201303120300PR_NEWS_USPR_____LA74924&DateId=20130312

Copyright (C) 2013 PR Newswire. All rights reserved

Comtex

View the original article here

Tuesday, March 12, 2013

Healthy Memphis: Fibroids and endometriosis can cause heavy menstrual pain ... - Memphis Commercial Appeal

AppId is over the quota
AppId is over the quota

What you should know

Many women suffer from heavy or painful periods. Others have bleeding between periods. Pain and bleeding might result from two conditions — fibroids or endometriosis — which cause extra tissue to grow in the pelvic area.

Fibroids and endometriosis are linked to estrogen, a female hormone. Estrogen is essential to the menstrual cycle. Every month, hormones cause the lining of a woman's womb (uterus) to build up. Too much or too little estrogen can affect fertility. Estrogen also affects many female characteristics such as low body hair, breast size, and the amount of fat in the hips and pelvis. Research shows that estrogen helps to maintain bone density and high-density lipoproteins (HDL, the "good" cholesterol). Regular exercise decreases body fat and the amount of estrogen the body produces.

Most American women will develop fibroids at some time. These non-cancerous uterine tumors are very common among women before age 50. After menopause, fibroids often shrink. African-American women over 35 years old also seem to be more likely to have fibroids.

Fibroids can be small or large. Many women do not realize they have fibroids until they have painful symptoms.

Fibroids can become so large that they press on surrounding tissue or even project outside of the uterus. Fibroids can cause an enlarged abdomen or painful sexual relations. Some women develop constipation or urinary problems. Others may suffer backaches from the pressure. Fibroids that grow inside the uterus can cause very heavy periods. Fibroids might also lead to multiple miscarriages or early labor.

Endometriosis occurs when tissue that normally lines the uterus grows somewhere else. Laparoscopy is often the best test to diagnosis endometriosis. The misplaced tissue might grow around the ovaries or fallopian tubes, at the bladder, or around the colon. Endometriosis can reduce or block fertility and create severe pain and bleeding.

Some women have a higher risk of endometriosis. It is more common among women who have never had children. Endometriosis also seems to run in families. Pelvic infections or injuries can create scar tissue or damaged cells that can block blood flow or encourage tissue growth.

There are many treatment options for both fibroids and endometriosis. Over-the-counter pain medication helps many women. Medical treatment might include birth control pills, an IUD (intrauterine device) that releases hormones, or other hormone prescriptions to change hormone levels. In severe cases, laparoscopy or laparotomy could be recommended to remove excess tissue or to cut off the supply of blood that feeds the misplaced or excess tissue. Other surgical procedures can include endometrial ablation or a D&C (dilatation and curettage) to remove the lining of the uterus. In extreme cases, a hysterectomy surgically removes the uterus altogether.

Fibroids are an important public health concern. They distress many women. Experts suspect that too many hysterectomies are done to treat the symptoms. Newer and less invasive techniques may work best for many women.

What you should do

Get a checkup for distressing symptoms of fibroids or endometriosis. A pelvic exam is likely. An ultrasound of the uterus and the ovaries may reveal the cause of heavy bleeding, pain, infertility or bloating. It is possible that your doctor will recommend a diagnostic laparoscopy if symptoms are severe.

Get help for cramps so bad that you often miss work or school or if you have pain or bleeding between periods.

Do your homework before agreeing to treatment options. Some treatments control symptoms. Other options can shrink excess tissue. Some choices are irreversible. Early menopause can occur if the ovaries are removed. A hysterectomy removes the womb (uterus).

Consider your age, severity of symptoms, condition, budget, and whether you want children later. For young women who might want start a family later, do not wait too long to get help for endometriosis. Severe endometriosis can make it harder to have children in the future.

Think about tactics to improve your pelvic area and lower your estrogen. Keep your body fat low. Exercise daily. Get pelvic muscles in shape. Work on your posture. Avoid foods and drinks that might increase estrogen.

Learn about causes of abnormal bleeding. Just before menopause and when it begins, women might not ovulate every month. This can cause heavy, lighter or irregular bleeding. Also, bleeding can be due to pregnancy or cancer.

For more information

Visit nlm.nih.gov/medlineplus/uterinefibroids.html and womenshealth.gov/publications/our-publications/fact-sheet/endometriosis.cfm.

Better Health: TAKE CHARGE! is provided by the Healthy Memphis Common Table: healthymemphis.org. This article supports the care and advice of your doctor.


View the original article here

Pregnant women to provide blood before delivery

AppId is over the quota
AppId is over the quota
Pregnant women to provide blood before delivery | Health News 2013-03-09 Display optionsMobile website Sign up | forgot your password You are here: Home ? News ? 2013-03-09 ? Article 267174 News Sports Business Entertainment Country Opinions Members Latest News Home - News Archived News Elections 2012 Entertainment Business Crime & Punishment Ghanaians Abroad Health Politics Regional Religion Sports Tabloid Others PollHot 10 Topics Rumour Mill Events SchedulePress Release World News Ghanaian Media Chronicle Daily Graphic Daily Guide District News Ghana News Agency Ghanaian Times Ghana Review Government News Joy Online Peace FM Radio XYZ The Statesman More Newsmedia Other Media allAfrica BBC-Africa News Africanews.com Advertisement Health News of Saturday, 9 March 2013

Source: GNA

Pregnant women to provide blood before delivery

Email this

Share This

Share This Page reddit Google Bookmarks del.icio.us StumbleUpon Newsvine livejournal Mixx it!

Print This

Comments (9)

« PrevNext » Expectant mothers are to get their relatives to provide two pints of blood for them as reserve before the day of their delivery as part of measures to reduce maternal mortality in the country.

This is to solve the problem of pregnant women losing the lives during delivery due to excessive loss of blood.

Madam Cecilia Arthur, a Senior Nursing Officer with the School of Public Health, University of Ghana- Legon, made this known at the weekend at a day’s health fair for women in Tema in commemoration with the 2013 International Women’s Day.

The workshop was organised by OJeane Clothing, in partnership with Sinel Specialist Hospital. Madam Arthur said the provision of blood for expectant women is a life saving policy.

She said studies over the years have shown that most women die during child delivery as they lose lots of blood either through caesarean section or spontaneous vaginal delivery. She added that in most cases, getting blood immediately for the mother becomes a problem during such emergencies leading to death.

Madam Arthur encouraged pregnant women and their relations to take the life saving policy seriously and provide the two pints of blood in advance.

On other pregnancy related issues, she indicated that every pregnant woman was required to at least attend ante-natal four times before delivery.

She noted that to prevent any complications and ensure that both the mother and the feotus are in good health, it was advisable that women immediately report to the hospital the moment they found out that they were pregnant.

Dr Michael McCartey, Gynaecologist at Sinel Specialist Hospital who spoke on fibroids encouraged women to report to the hospital early for treatment.

Dr McCartey said some of the symptoms of fibroid include heavy bleeding during menstruation, prolonged menstruation, protruding stomach, abdominal pains and movements in the stomach even though the woman is not pregnant.

He gave the assurance that not all fibroids require operations nor lead to infertility in women and therefore encouraged women not to be afraid to take steps in getting medical attention.

Mrs Jeanne O. Iddisah, Programme Director for the fair, said the programme was under the auspices of the Ministry of Gender, Children and Social Protection.

She said the fair which was on the theme: “Pregnancy and its aftermath: the modern day conscious woman,” was to give women the platform to learn about reproductive health issues, raise and gain more awareness about the increasing rate of maternal mortality among matters.

Comments:
This article has 9 comments, give your commentSelf AdvertsCreate one » Sell your property! Fastest on the GhanaWeb portal About Us Advertising Feedback Sitemap Copyright © 1994 - 2013 GhanaWeb. All rights reserved.


View the original article here